LOX and renal cell carcinoma: Recently, lysyl oxidase (LOX) has been identified as an important regulator of hypoxia-induced tumor progression via an HIF-1α-dependent mechanism in a variety of human cancers including breast, colon, head and neck, ovarian, prostate and renal cell carcinomas (20–24).